Web-Based Nomogram for Individualized Survival Prediction in Patients with Pleomorphic Xanthoastrocytoma: A SEER Analysis

Background: Pleomorphic xanthoastrocytoma (PXA) is a rare astrocytic neoplasm with variable clinical behavior. To better characterize survival outcomes and prognostic factors in patients with malignant PXA tumors, we performed a population-based analysis using data from the SEER program. Methods: We queried the SEER database using ICD-O-3 histology code 9424/3 to identify patients diagnosed with PXA between 2000 and 2022. Univariate and multivariable Cox regression were performed on demographic, tumor, and treatment variables to identify independent prognostic factors, with Kaplan–Meier Curves estimating survival for these same variables. To predict patient-specific 5- and 10-year survival probabilities, we built a web-based nomogram. Results: Overall survival rates of our 597 PXA patients were 92.2%, 86.7%, 81.5%, 74.6%, and 68.3% at 1-, 2-, 3-, 5-, and 10-years, respectively. In multivariable analysis, age ≥50 years was independently associated with significantly worse OS (p < 0.001). Larger tumor size (3.0–6.0 cm or >6 cm) also predicted poorer outcomes compared to smaller tumor size (<3.0 cm) (p < 0.01). When compared to patients who received gross total resection alone (GTR), patients who received GTR with chemotherapy and radiation, GTR with radiation, subtotal resection (STR) with chemotherapy and radiation, and STR with radiation all had worse OS (p < 0.01). Interestingly, patients who received STR alone had no statistically significant difference in OS compared to patients who received GTR alone (p > 0.05). Conclusions: We conducted the largest retrospective cohort study and provide the first nomogram-based app developed for PXA patients as a means of analyzing survival. Our aim for this app is to guide clinicians in more meaningful discussions with their patients and to provide an evidence-based tool that is easily deployable in the clinic.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2026-11-16
DOI
https://doi.org/10.3390/cancers18223661
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Web-Based Nomogram for Individualized Survival Prediction in Patients with Pleomorphic Xanthoastrocytoma: A SEER Analysis

Austin R. Hoggarth, Brendan J. Klein, Abhishek S. Bhutada, Srijan Adhikari et al.
1 links
Cancers
Glioma Diagnosis and Treatment
article

Web-Based Nomogram for Individualized Survival Prediction in Patients with Pleomorphic Xanthoastrocytoma: A SEER Analysis

Austin R. Hoggarth, Brendan J. Klein, Abhishek S. Bhutada, Srijan Adhikari, Julianna Barbaro
article en

Abstract

Background: Pleomorphic xanthoastrocytoma (PXA) is a rare astrocytic neoplasm with variable clinical behavior. To better characterize survival outcomes and prognostic factors in patients with malignant PXA tumors, we performed a population-based analysis using data from the SEER program. Methods: We queried the SEER database using ICD-O-3 histology code 9424/3 to identify patients diagnosed with PXA between 2000 and 2022. Univariate and multivariable Cox regression were performed on demographic, tumor, and treatment variables to identify independent prognostic factors, with Kaplan–Meier Curves estimating survival for these same variables. To predict patient-specific 5- and 10-year survival probabilities, we built a web-based nomogram. Results: Overall survival rates of our 597 PXA patients were 92.2%, 86.7%, 81.5%, 74.6%, and 68.3% at 1-, 2-, 3-, 5-, and 10-years, respectively. In multivariable analysis, age ≥50 years was independently associated with significantly worse OS (p < 0.001). Larger tumor size (3.0–6.0 cm or >6 cm) also predicted poorer outcomes compared to smaller tumor size (<3.0 cm) (p < 0.01). When compared to patients who received gross total resection alone (GTR), patients who received GTR with chemotherapy and radiation, GTR with radiation, subtotal resection (STR) with chemotherapy and radiation, and STR with radiation all had worse OS (p < 0.01). Interestingly, patients who received STR alone had no statistically significant difference in OS compared to patients who received GTR alone (p > 0.05). Conclusions: We conducted the largest retrospective cohort study and provide the first nomogram-based app developed for PXA patients as a means of analyzing survival. Our aim for this app is to guide clinicians in more meaningful discussions with their patients and to provide an evidence-based tool that is easily deployable in the clinic.

CancersVol. 18(22)
Carilion Clinic (US), Virginia Tech (US)
Good health and well-being
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon